CN1173736C - 白细胞介素-18抑制剂抑制肿瘤转移的用途 - Google Patents

白细胞介素-18抑制剂抑制肿瘤转移的用途 Download PDF

Info

Publication number
CN1173736C
CN1173736C CNB008106894A CN00810689A CN1173736C CN 1173736 C CN1173736 C CN 1173736C CN B008106894 A CNB008106894 A CN B008106894A CN 00810689 A CN00810689 A CN 00810689A CN 1173736 C CN1173736 C CN 1173736C
Authority
CN
China
Prior art keywords
cells
hse
adhesion
tnf
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008106894A
Other languages
English (en)
Chinese (zh)
Other versions
CN1364086A (zh
Inventor
C
C·迪纳洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA, Yeda Research and Development Co Ltd filed Critical Ares Trading SA
Publication of CN1364086A publication Critical patent/CN1364086A/zh
Application granted granted Critical
Publication of CN1173736C publication Critical patent/CN1173736C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB008106894A 1999-07-22 2000-07-17 白细胞介素-18抑制剂抑制肿瘤转移的用途 Expired - Lifetime CN1173736C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13104799A IL131047A0 (en) 1999-07-22 1999-07-22 Use of il-18 inhibitors
IL131047 1999-07-22

Publications (2)

Publication Number Publication Date
CN1364086A CN1364086A (zh) 2002-08-14
CN1173736C true CN1173736C (zh) 2004-11-03

Family

ID=11073044

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008106894A Expired - Lifetime CN1173736C (zh) 1999-07-22 2000-07-17 白细胞介素-18抑制剂抑制肿瘤转移的用途

Country Status (31)

Country Link
US (1) US7741276B2 (enExample)
EP (1) EP1206274B1 (enExample)
JP (1) JP4827352B2 (enExample)
KR (1) KR100682219B1 (enExample)
CN (1) CN1173736C (enExample)
AR (1) AR024907A1 (enExample)
AT (1) ATE363288T1 (enExample)
AU (1) AU782478B2 (enExample)
BG (1) BG65800B1 (enExample)
BR (1) BR0012675A (enExample)
CA (1) CA2380216C (enExample)
CY (1) CY1107932T1 (enExample)
CZ (1) CZ302114B6 (enExample)
DE (2) DE60035049T2 (enExample)
DK (1) DK1206274T3 (enExample)
EA (1) EA005419B1 (enExample)
EE (1) EE04838B1 (enExample)
ES (1) ES2186596T3 (enExample)
HK (1) HK1048248B (enExample)
HU (1) HU228780B1 (enExample)
IL (2) IL131047A0 (enExample)
MX (1) MXPA02000838A (enExample)
NO (1) NO329827B1 (enExample)
NZ (1) NZ516535A (enExample)
PL (1) PL202477B1 (enExample)
PT (1) PT1206274E (enExample)
SK (1) SK287522B6 (enExample)
TR (1) TR200200169T2 (enExample)
UA (1) UA73745C2 (enExample)
WO (1) WO2001007480A2 (enExample)
ZA (1) ZA200200390B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12942002A3 (sk) 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
BR0210904A (pt) * 2001-05-16 2005-08-16 Yeda Res & Dev Uso de inibidores de il-18 para o tratamento ou prevenção de sepse
RU2225720C1 (ru) * 2002-08-12 2004-03-20 Научно-исследовательский институт онкологии Томского научного центра СО РАМН Средство, повышающее противоопухолевую и антиметастатическую активность циклофосфана
BR0315155A (pt) * 2002-10-08 2005-08-16 Ares Trading Sa Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
US9812033B2 (en) * 2013-03-06 2017-11-07 Venkatesh R. Chari Tactile graphic display
CA3259975A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
EP4646433A1 (en) 2023-01-06 2025-11-12 Lassen Therapeutics, Inc. Anti-il-18bp antibodies
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ299210A (en) * 1992-09-02 2000-08-25 Isis Pharmaceuticals Inc Treating diseases characterised by changes in intercellular adhesion molecules using coding sequences hybridizable with those encoding proteins involved in synthesis of such molecules
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use

Also Published As

Publication number Publication date
BRPI0012675B1 (pt) 2001-02-01
HU228780B1 (en) 2013-05-28
BRPI0012675B8 (enExample) 2021-05-25
DE60035049T2 (de) 2007-09-27
IL147675A (en) 2009-05-04
AR024907A1 (es) 2002-10-30
KR20020027493A (ko) 2002-04-13
HUP0202107A2 (en) 2002-10-28
EA200200189A1 (ru) 2002-12-26
CZ2002195A3 (cs) 2002-06-12
CN1364086A (zh) 2002-08-14
NO20020153L (no) 2002-03-11
DK1206274T3 (da) 2007-08-13
JP4827352B2 (ja) 2011-11-30
NO329827B1 (no) 2011-01-03
PT1206274E (pt) 2007-07-06
NZ516535A (en) 2004-04-30
TR200200169T2 (tr) 2002-06-21
HK1048248A1 (en) 2003-03-28
HK1048248B (zh) 2005-04-22
JP2003505472A (ja) 2003-02-12
UA73745C2 (en) 2005-09-15
US20080003216A1 (en) 2008-01-03
ES2186596T3 (es) 2007-11-16
SK287522B6 (sk) 2011-01-04
PL202477B1 (pl) 2009-06-30
CZ302114B6 (cs) 2010-10-20
AU782478B2 (en) 2005-08-04
WO2001007480A2 (en) 2001-02-01
BG65800B1 (bg) 2009-12-31
EE04838B1 (et) 2007-06-15
ATE363288T1 (de) 2007-06-15
HUP0202107A3 (en) 2005-01-28
EP1206274A2 (en) 2002-05-22
AU5843200A (en) 2001-02-13
BG106311A (en) 2002-08-30
EP1206274B1 (en) 2007-05-30
CY1107932T1 (el) 2013-09-04
EE200200032A (et) 2003-02-17
IL131047A0 (en) 2001-01-28
SK882002A3 (en) 2002-07-02
MXPA02000838A (es) 2002-07-30
CA2380216A1 (en) 2001-02-01
KR100682219B1 (ko) 2007-02-12
CA2380216C (en) 2012-01-31
NO20020153D0 (no) 2002-01-11
EA005419B1 (ru) 2005-02-24
DE60035049D1 (de) 2007-07-12
ES2186596T1 (es) 2003-05-16
BR0012675A (pt) 2002-04-09
ZA200200390B (en) 2003-04-30
PL353732A1 (en) 2003-12-01
WO2001007480A3 (en) 2001-05-10
US7741276B2 (en) 2010-06-22
DE1206274T1 (de) 2002-11-14

Similar Documents

Publication Publication Date Title
US7741276B2 (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
JP3798426B2 (ja) 自己免疫疾患の治療におけるｉｌ−１２およびｉｌ−１２アンタゴニストの使用
CN1133464C (zh) 控制释放可溶性受体的药物组合物
CN1075387C (zh) 含有il－6拮抗剂的抗肿瘤剂的作用增强剂
HRP950052A2 (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
JPH04507195A (ja) 腫瘍壊死因子結合リガンド
WO2002096461A1 (en) Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
AU2003301114B2 (en) Uses of mammalian cytokine; related reagents
CN1921886A (zh) 调节细胞因子活性的方法；相关药剂
DK2219452T3 (en) PROCESSES FOR THE TREATMENT OF scleroderma.
CA2306790A1 (en) Application of tnf antagonists as medicaments for treating septic diseases
JPH0725785A (ja) インターロイキン−６の医薬組成物
CN1742574A (zh) 器官保存液及其制法和应用
Zhao et al. Exploration of Cytokine Signaling in Clinical Management of Hepatocellular Carcinoma
Jiang Increased core temperature during febrile disease modulates cytokine expression, enhances host defense, and improves survival in bacterial infection
SERODY et al. KENNETH R. COOKE

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ALEIX TRADE CO., LTD.

Free format text: FORMER OWNER: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Effective date: 20030213

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20030213

Address after: Swiss Marx

Applicant after: Ares Trading S. A.

Address before: Voight, Israel

Applicant before: Yeda Res & Dev

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1048248

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20041103